Antigen-Specific Cytotoxicity by Invariant NKT Cells In Vivo Is CD95/CD178-Dependent and Is Correlated with Antigenic Potency

Invariant NKT (iNKT) cells are a unique subset of T lymphocytes that rapidly carry out effector functions following activation with glycolipid Ags, such as the model Ag α-galactosylceramide. Numerous studies have investigated the mechanisms leading to Th1 and Th2 cytokine production by iNKT cells, as well as the effects of the copious amounts of cytokines these cells produce. Less is known, however, about the mechanisms of iNKT cell cytotoxicity. In this study, we investigated the effect of Ag availability and strength, as well as the molecules involved in iNKT cytotoxicity. We demonstrate that the iNKT cell cytotoxicity in vivo correlates directly with the amount of CD1d expressed by the targets as well as the TCR affinity for the target glycolipid Ag. iNKT cells from spleen, liver, and thymus were comparable in their cytotoxicity in vitro. Surprisingly, we show that the Ag-specific cytotoxicity of iNKT cells in vivo depended almost exclusively on the interaction of CD95 (Fas) with CD178 (FasL), and that this mechanism can be efficiently used for tumor protection. Therefore, unlike NK cells, which rely mostly on perforin/granzyme-mediated mechanisms, the Ag-specific cytotoxicity of iNKT cells in vivo is largely restricted to the CD95/CD178 pathway.

[1]  N. Nagarajan,et al.  Mechanisms for Glycolipid Antigen-Driven Cytokine Polarization by Vα14i NKT Cells , 2009, The Journal of Immunology.

[2]  T. Nakayama,et al.  Clinical applications of natural killer T cell–based immunotherapy for cancer , 2008, Cancer science.

[3]  J. Berzofsky,et al.  NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis. , 2007, Trends in immunology.

[4]  R. Steinman,et al.  Cross-presentation of glycolipid from tumor cells loaded with α-galactosylceramide leads to potent and long-lived T cell–mediated immunity via dendritic cells , 2007, The Journal of experimental medicine.

[5]  M. Kronenberg,et al.  The unique role of natural killer T cells in the response to microorganisms , 2007, Nature Reviews Microbiology.

[6]  M. Taniguchi,et al.  Tumor Cells Loaded with α-Galactosylceramide Induce Innate NKT and NK Cell-Dependent Resistance to Tumor Implantation in Mice1 , 2007, The Journal of Immunology.

[7]  M. Smyth,et al.  CD1-restricted T cells and tumor immunity. , 2007, Current topics in microbiology and immunology.

[8]  Xinguo Jiang,et al.  Expression of high levels of human proteinase inhibitor 9 blocks both perforin/granzyme and Fas/Fas ligand-mediated cytotoxicity. , 2007, Cellular immunology.

[9]  S. Mattarollo,et al.  Chemotherapy pretreatment sensitizes solid tumor‐derived cell lines to Vα24+ NKT cell‐mediated cytotoxicity , 2006, International journal of cancer.

[10]  R. Steinman,et al.  Glycolipid α-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice , 2006 .

[11]  Xianzhu Wu,et al.  Oral Nickel Tolerance: Fas Ligand-Expressing Invariant NK T Cells Promote Tolerance Induction by Eliciting Apoptotic Death of Antigen-Carrying, Effete B Cells1 , 2006, The Journal of Immunology.

[12]  I. Wilson,et al.  Design of natural killer T cell activators: structure and function of a microbial glycosphingolipid bound to mouse CD1d. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[13]  M. Kronenberg,et al.  Immediate antigen‐specific effector functions byTCR‐transgenic CD8+ NKT cells , 2006, European journal of immunology.

[14]  S. Ogawa,et al.  CD1d expression level in tumor cells is an important determinant for anti-tumor immunity by natural killer T cells , 2006, Leukemia & lymphoma.

[15]  D. Pellicci,et al.  Differential antitumor immunity mediated by NKT cell subsets in vivo , 2005, The Journal of experimental medicine.

[16]  M. Kronenberg,et al.  Vα14i NKT Cells Are Innate Lymphocytes That Participate in the Immune Response to Diverse Microbes , 2005, Journal of Clinical Immunology.

[17]  S. Nutt,et al.  Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer , 2005, The Journal of experimental medicine.

[18]  G. Cimino,et al.  CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis , 2005, Leukemia.

[19]  D. Ho,et al.  Recognition of bacterial glycosphingolipids by natural killer T cells , 2005, Nature.

[20]  B. Beutler,et al.  Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections , 2005, Nature.

[21]  Mitchell Kronenberg,et al.  Toward an understanding of NKT cell biology: progress and paradoxes. , 2005, Annual review of immunology.

[22]  M. Tsuji,et al.  The C-glycoside analogue of the immunostimulant alpha-galactosylceramide (KRN7000): synthesis and striking enhancement of activity. , 2004, Angewandte Chemie.

[23]  T. Yamamura,et al.  The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells. , 2004, The Journal of clinical investigation.

[24]  V. Callea,et al.  CD1d is expressed on B‐chronic lymphocytic leukemia cells and mediates α‐galactosylceramide presentation to natural killer T lymphocytes , 2004, International journal of cancer.

[25]  Franca Ronchese,et al.  The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. , 2004, Journal of immunological methods.

[26]  Mario Roederer,et al.  Guidelines for the presentation of flow cytometric data. , 2004, Methods in cell biology.

[27]  M. Tsuji,et al.  Superior Protection against Malaria and Melanoma Metastases by a C-glycoside Analogue of the Natural Killer T Cell Ligand α-Galactosylceramide , 2003, The Journal of experimental medicine.

[28]  Jelena S. Bezbradica,et al.  Another View of T Cell Antigen Recognition: Cooperative Engagement of Glycolipid Antigens by Va14Ja18 Natural TCR 1 , 2003, The Journal of Immunology.

[29]  H. Ikeda,et al.  CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  K. Weinberg,et al.  Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells , 2003, Leukemia.

[31]  Jelena S. Bezbradica,et al.  Another view of T cell antigen recognition: cooperative engagement of glycolipid antigens by Va14Ja18 natural T(iNKT) cell receptor [corrected]. , 2003, Journal of immunology.

[32]  I. N. Crispe,et al.  Hepatic T cells and liver tolerance , 2003, Nature Reviews Immunology.

[33]  M. Kronenberg,et al.  CD1 tetramers: a powerful tool for the analysis of glycolipid-reactive T cells. , 2002, Journal of immunological methods.

[34]  L. Kaer,et al.  IFN-γ–mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, α-galactosylceramide , 2002 .

[35]  P. Henkart,et al.  Surface Cathepsin B Protects Cytotoxic Lymphocytes from Self-destruction after Degranulation , 2002, The Journal of experimental medicine.

[36]  R. Steinman,et al.  Prolonged IFN-γ–producing NKT response induced with α-galactosylceramide–loaded DCs , 2002, Nature Immunology.

[37]  M. Kronenberg,et al.  The unconventional lifestyle of NKT cells , 2002, Nature Reviews Immunology.

[38]  M. Smyth,et al.  A Critical Role for Natural Killer T Cells in Immunosurveillance of Methylcholanthrene-induced Sarcomas , 2002, The Journal of experimental medicine.

[39]  R. Bleackley,et al.  Cytotoxic T lymphocytes: all roads lead to death , 2002, Nature Reviews Immunology.

[40]  M. Smyth,et al.  NKT cells - conductors of tumor immunity? , 2002, Current opinion in immunology.

[41]  H. Hirai,et al.  Cutting Edge: Analysis of Human Vα24+CD8+ NK T Cells Activated by α-Galactosylceramide-Pulsed Monocyte-Derived Dendritic Cells , 2002, The Journal of Immunology.

[42]  T. Reichert,et al.  Regulation of CD1d expression by murine tumor cells: Escape from immunosurveillance or alternate target molecules? , 2002, International journal of cancer.

[43]  R. Brutkiewicz,et al.  Natural killer T (NKT) cells and their role in antitumor immunity. , 2002, Critical reviews in oncology/hematology.

[44]  K. Ando,et al.  Human umbilical cord blood NK T cells kill tumors by multiple cytotoxic mechanisms. , 2002, Human immunology.

[45]  D. Pellicci,et al.  Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. , 2002, Blood.

[46]  Scott N. Mueller,et al.  Progression of Armed CTL from Draining Lymph Node to Spleen Shortly After Localized Infection with Herpes Simplex Virus 11 , 2002, The Journal of Immunology.

[47]  T. Yamamura,et al.  A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells , 2001, Nature.

[48]  R. Seeger,et al.  Human NKT Cells Mediate Antitumor Cytotoxicity Directly by Recognizing Target Cell CD1d with Bound Ligand or Indirectly by Producing IL-2 to Activate NK Cells1 , 2001, The Journal of Immunology.

[49]  P. Knolle,et al.  Neighborhood politics: the immunoregulatory function of organ-resident liver endothelial cells. , 2001, Trends in immunology.

[50]  Y. Iwakura,et al.  Critical contribution of IFN‐γ and NK cells, but not perforin‐mediated cytotoxicity, to anti‐metastatic effect of α‐galactosylceramide , 2001 .

[51]  S. Seki,et al.  Mechanisms of the Antimetastatic Effect in the Liver and of the Hepatocyte Injury Induced by α-Galactosylceramide in Mice , 2001, The Journal of Immunology.

[52]  Y. Tanaka,et al.  TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells. , 2001, Blood.

[53]  R. Dummer,et al.  Comparative analysis of immunocritical melanoma markers in the mouse melanoma cell lines B16, K1735 and S91-M3 , 2001, Melanoma research.

[54]  M. Smyth,et al.  NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. , 2001, International immunology.

[55]  I. Serizawa,et al.  Antitumor activity of alpha-galactosylceramide, KRN7000, in mice with the melanoma B16 hepatic metastasis and immunohistological study of tumor infiltrating cells. , 2001, Oncology research.

[56]  F. Chisari,et al.  Natural Killer T Cell Activation Inhibits Hepatitis B Virus Replication in Vivo , 2000, The Journal of experimental medicine.

[57]  M. Kronenberg,et al.  Tracking the Response of Natural Killer T Cells to a Glycolipid Antigen Using Cd1d Tetramers , 2000, The Journal of experimental medicine.

[58]  K. Tadokoro,et al.  α-Glycosylceramides Enhance the Antitumor Cytotoxicity of Hepatic Lymphocytes Obtained from Cancer Patients by Activating CD3−CD56+ NK Cells In Vitro , 2000, The Journal of Immunology.

[59]  L. Kaer,et al.  The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes. , 2000, International immunology.

[60]  L. Kaer,et al.  Relative contribution of NK and NKT cells to the anti-metastatic activities of IL-12. , 2000, International immunology.

[61]  K. Tadokoro,et al.  Analysis of Human Vα24+ CD4+ NKT Cells Activated by α-Glycosylceramide-Pulsed Monocyte-Derived Dendritic Cells , 2000, The Journal of Immunology.

[62]  H. Macdonald,et al.  Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells , 2000, European journal of immunology.

[63]  K. Tadokoro,et al.  Human invariant Vα24+ natural killer T cells activated by α‐galactosylceramide (KRN7000) have cytotoxic anti‐tumour activity through mechanisms distinct from T cells and natural killer cells , 2000, Immunology.

[64]  M. Taniguchi,et al.  Augmentation of Vα14 Nkt Cell–Mediated Cytotoxicity by Interleukin 4 in an Autocrine Mechanism Resulting in the Development of Concanavalin a–Induced Hepatitis , 2000, The Journal of experimental medicine.

[65]  河野 鉄 CD1d-restricted and TCR-mediated activation of V α14 NKT cells by glycosylceramides , 2000 .

[66]  Y. Koezuka,et al.  Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. , 1999, Journal of immunology.

[67]  T. Iizasa,et al.  Antitumor Cytotoxicity Mediated by Ligand-activated Human Vα24 NKT Cells , 1999 .

[68]  M. Taniguchi,et al.  Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide. , 1999, Journal of immunology.

[69]  A. Ohta,et al.  The Natural Killer T (NKT) Cell Ligand α-Galactosylceramide Demonstrates Its Immunopotentiating Effect by Inducing Interleukin (IL)-12 Production by Dendritic Cells and IL-12 Receptor Expression on NKT Cells , 1999, The Journal of experimental medicine.

[70]  M. Kronenberg,et al.  CD1d-mediated Recognition of an α-Galactosylceramide by Natural Killer T Cells Is Highly Conserved through Mammalian Evolution , 1998, The Journal of experimental medicine.

[71]  L. Herzenberg,et al.  CD1 expression defines subsets of follicular and marginal zone B cells in the spleen: beta 2-microglobulin-dependent and independent forms. , 1998, Journal of immunology.

[72]  P. Möller,et al.  T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas. , 1998, Journal of immunology.

[73]  Y. Tanaka,et al.  Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[74]  U. Kavita,et al.  CD1.1 expression by mouse antigen-presenting cells and marginal zone B cells. , 1998, Journal of immunology.

[75]  R. Nakagawa,et al.  Treatment of hepatic metastasis of the colon26 adenocarcinoma with an alpha-galactosylceramide, KRN7000. , 1998, Cancer research.

[76]  L. Kaer,et al.  Cutting Edge: Critical Role of NK1+ T Cells in IL-12-Induced Immune Responses In Vivo , 1998, The Journal of Immunology.

[77]  K. Takeda,et al.  Critical role of NK1+ T cells in IL-12-induced immune responses in vivo. , 1998, Journal of immunology.

[78]  T. Inamoto,et al.  Antitumor activity of alpha-galactosylceramide, KRN7000, in mice with EL-4 hepatic metastasis and its cytokine production. , 1998, Oncology research.

[79]  Hiroshi Sato,et al.  Requirement for Vα14 NKT Cells in IL-12-Mediated Rejection of Tumors , 1997 .

[80]  Hiroshi Sato,et al.  CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. , 1997, Science.

[81]  N. Minato,et al.  Involvement of NK1+ CD4- CD8- alphabeta T cells and endogenous IL-4 in non-MHC-restricted rejection of embryonal carcinoma in genetically resistant mice. , 1997, Journal of immunology.

[82]  S. Park,et al.  Mouse CD1-specific NK1 T cells: development, specificity, and function. , 1997, Annual review of immunology.

[83]  L. McDonald,et al.  A Cytosolic Granzyme B Inhibitor Related to the Viral Apoptotic Regulator Cytokine Response Modifier A Is Present in Cytotoxic Lymphocytes* , 1996, The Journal of Biological Chemistry.

[84]  K. Takeda,et al.  Interleukin‐12 induces cytotoxic NK1+αβ T cells in the lungs of euthymic and athymic mice , 1996 .

[85]  K. Takeda,et al.  Liver NK1.1+ CD4+ alpha beta T cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis. , 1996, Journal of immunology.

[86]  K. Takeda,et al.  LPS induces NK1.1+ alpha beta T cells with potent cytotoxicity in the liver of mice via production of IL-12 from Kupffer cells. , 1996, Journal of immunology.

[87]  T. Natori,et al.  Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice. , 1995, Journal of medicinal chemistry.

[88]  K. Takeda,et al.  Cytotoxic NK1.1 Ag+ alpha beta T cells with intermediate TCR induced in the liver of mice by IL-12. , 1995, Journal of immunology.

[89]  R. Herberman,et al.  Lymphocyte-mediated cytotoxicity. , 1987, Pediatric annals.